SCHEMBL1745140

SCHEMBL1745140

Cc1cc(OC/C=C(/c2ccc(Cl)cc2)c2ccc(C#CCN3CCOCC3)cc2)ccc1C(C)C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.47
ALDH1A1 P00352 4/20 0.47
TDP1 Q9NUW8 1/20 0.47
PPARD Q03181 3/20 0.42
FKBP1A P62942 1/20 0.40
LMNA P02545 2/20 0.40
MAPK1 P28482 1/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
MMP13 P45452 2/20 0.38
MMP2 P08253 1/20 0.37
MMP3 P08254 1/20 0.37
TP53 P04637 1/20 0.36
PPARG P37231 1/20 0.36
PPARA Q07869 1/20 0.36
HPGD P15428 1/20 0.36
HTT P42858 1/20 0.36
CNR1 P21554 1/20 0.36
CNR2 P34972 1/20 0.36
SLC6A4 P31645 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1746379 1.00 KDM4E (0.47) KDM4EALDH1A1TDP1PPARDFKBP1A
SCHEMBL1745146 1.00 KDM4E (0.47) KDM4EALDH1A1TDP1PPARDFKBP1A
SCHEMBL29801093 1.00 KDM4E (0.47) KDM4EALDH1A1TDP1PPARDFKBP1A
SCHEMBL1746471 0.89 KDM4E (0.43) KDM4EALDH1A1TDP1PPARDFKBP1A
SCHEMBL1744562 0.88 PPARD (0.46) KDM4EALDH1A1TDP1PPARDLMNA
SCHEMBL1744561 0.88 PPARD (0.46) KDM4EALDH1A1TDP1PPARDLMNA
SCHEMBL1744564 0.88 PPARD (0.46) KDM4EALDH1A1TDP1PPARDLMNA
SCHEMBL1744825 0.87 PPARD (0.55) KDM4EALDH1A1TDP1PPARDPPARG
SCHEMBL1744830 0.87 PPARD (0.55) KDM4EALDH1A1TDP1PPARDPPARG
SCHEMBL1744826 0.87 PPARD (0.55) KDM4EALDH1A1TDP1PPARDPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250360139-A1 USE OF A PPAR-DELTA AGONIST FOR REDUCING LOSS OF MUSCLE STRENGTH, MUSCLE MASS, OR TYPE I MUSCLE FIBERS IN AN IMMOBILIZED LIMB VTV THERAPEUTICS LLC (US) 2025-11-27 US claimed
US-20220370467-A1 USING OF A PPAR-DELTA AGONIST IN THE TREATMENT OF KIDNEY DISEASE WASHINGTON UNIVERSITY 2022-11-24 US claimed
CN-114727976-A Use of PPAR-delta agonists in the treatment of renal disease 雷内奥制药公司 2022-07-08 CN claimed
US-20220117972-A1 USE OF PPAR-DELTA AGONISTS IN THE TREATMENT OF MITOCHONDRIAL MYOPATHY RENEO PHARMACEUTICALS, INC. 2022-04-21 US claimed
US-20220023306-A1 USE OF A PPAR-DELTA AGONIST IN THE TREATMENT OF FATTY ACID OXIDATION DISORDERS (FAOD) RENEO PHARMACEUTICALS, INC. 2022-01-27 US claimed
EP-3927718-A1 USE OF PPAR-DELTA AGONISTS IN THE TREATMENT OF MITOCHONDRIAL MYOPATHY Reneo Pharmaceuticals, Inc. (US) 2021-12-29 EP claimed
CN-113747891-A Use of PPAR delta agonists in the treatment of Fatty Acid Oxidation Disorders (FAOD) 雷内奥制药公司 2021-12-03 CN claimed
CN-113710683-A Use of PPAR-delta agonists in the treatment of mitochondrial myopathy 雷内奥制药公司 2021-11-26 CN claimed
US-20210188758-A1 PHENOXY ACETIC ACIDS AND PHENYL PROPIONIC ACIDS AS PPAR DELTA AGONISTS VTVX HOLDINGS II LLC 2021-06-24 US claimed
WO-2021055725-A1 USE OF A PPAR-DELTA AGONIST IN THE TREATMENT OF KIDNEY DISEASE RENEO PHARMACEUTICALS, INC. (US) 2021-03-25 WO claimed
US-20170216303-A1 PHENOXY ACETIC ACIDS AND PHENYL PROPIONIC ACIDS AS PPAR DELTA AGONISTS HIGH POINT PHARMACEUTICALS, LLC 2017-08-03 US claimed
US-9663481-B2 Phenoxy acetic acids and phenyl propionic acids as PPARδ agonists VTV THERAPEUTICS LLC (US) 2017-05-30 US claimed
EP-3043789-A1 USE OF A PPAR-DELTA AGONIST FOR TREATING MUSCLE ATROPHY vTv Therapeutics LLC (US) 2016-07-20 EP claimed
US-20150072985-A1 USE OF A PPAR-DELTA AGONIST FOR TREATING MUSCLE ATROPHY VTVX HOLDINGS I LLC 2015-03-12 US claimed
WO-2015035171-A1 USE OF A PPAR-DELTA AGONIST FOR TREATING MUSCLE ATROPHY HIGH POINT PHARMACEUTICALS, LLC (US) 2015-03-12 WO claimed
US-20140024645-A1 PHENOXY ACETIC ACIDS AND PHENYL PROPIONIC ACIDS AS PPAR DELTA AGONISTS HIGH POINT PHARMACEUTICALS, LLC (US) 2014-01-23 US claimed
US-8362016-B2 Phenyl propionic acids as PPAR delta activators HIGH POINT PHARMACEUTICALS, LLC (US) 2013-01-29 US claimed
EP-1979311-B1 PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS HIGH POINT PHARMACEUTICALS LLC (US) 2012-06-13 EP claimed
US-20110245244-A1 PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS HIGH POINT PHARMACEUTICALS, LLC (US) 2011-10-06 US claimed
US-20090093484-A1 NOVEL COMPOUNDS, THEIR PREPARATION AND USE VTVX HOLDINGS II LLC 2009-04-09 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150072985-A1 USE OF A PPAR-DELTA AGONIST FOR TREATING MUSCLE ATROPHY PPARA, PPARD, PPARG KDM4E 2114/4885ALDH1A1 1667/4885TDP1 3257/4885
US-20220370467-A1 USING OF A PPAR-DELTA AGONIST IN THE TREATMENT OF KIDNEY DISEASE PPARG, PPARA, PPARD KDM4E 4647/4885ALDH1A1 3441/4885TDP1 4243/4885
US-20090093484-A1 NOVEL COMPOUNDS, THEIR PREPARATION AND USE PPARG, PPARD, PPARA KDM4E 3817/4885ALDH1A1 1084/4885TDP1 4446/4885
US-20250360139-A1 USE OF A PPAR-DELTA AGONIST FOR REDUCING LOSS OF MUSCLE STRENGTH, MUSCLE MASS, OR TYPE I MUSCLE FIBERS IN AN IMMOBILIZED LIMB PPARA, PPARG, PPARD KDM4E 1814/4885ALDH1A1 796/4885TDP1 3722/4885
US-20170216303-A1 PHENOXY ACETIC ACIDS AND PHENYL PROPIONIC ACIDS AS PPAR DELTA AGONISTS PPARG, PPARA, PPARD KDM4E 3151/4885ALDH1A1 380/4885TDP1 3921/4885
US-20220117972-A1 USE OF PPAR-DELTA AGONISTS IN THE TREATMENT OF MITOCHONDRIAL MYOPATHY PPARD, PPARA, MTPN KDM4E 3961/4885ALDH1A1 1914/4885TDP1 963/4885
US-20110245244-A1 PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS PPARG, PPARA, PPARD KDM4E 2717/4885ALDH1A1 198/4885TDP1 3870/4885
US-20210188758-A1 PHENOXY ACETIC ACIDS AND PHENYL PROPIONIC ACIDS AS PPAR DELTA AGONISTS PPARG, PPARA, PPARD KDM4E 3509/4885ALDH1A1 487/4885TDP1 2826/4885
US-20140024645-A1 PHENOXY ACETIC ACIDS AND PHENYL PROPIONIC ACIDS AS PPAR DELTA AGONISTS PPARG, PPARA, PPARD KDM4E 3151/4885ALDH1A1 380/4885TDP1 3921/4885
US-20220023306-A1 USE OF A PPAR-DELTA AGONIST IN THE TREATMENT OF FATTY ACID OXIDATION DISORDERS (FAOD) PPARD, ACOX1, CPT1A KDM4E 4348/4885ALDH1A1 326/4885TDP1 2994/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.